ArticleThe international journal of neuropsychopharmacology2017
5-HT2A Agonists: A Novel Therapy for Functional Neurological Disorders?
Article in The international journal of neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Impact of Psilocybin on Motor Function in Healthy Participants: A Phase 1, Randomised, Triple-Blind, Dose-Finding Study.CNS drugs · 2026Trial
- After the Trip: A Qualitative Study of Healthy Individuals' Motor Experiences Following Different Doses of Psilocybin.Brain and behavior · 2026Article
- A structural overview of G-protein-coupled receptors in neurological disorders.Acta pharmacologica Sinica · 2026Review
- Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study.Acta neuropsychiatrica · 2025Article
- Psychedelics meet human brain organoids: insights into proteomics and potential for Alzheimer's disease treatment.Frontiers in dementia · 2025Review
- Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants.Psychiatric research and clinical practice · 2024Article
- microRNA-140-3p protects hippocampal neuron against pyroptosis to attenuate sevoflurane inhalation-induced post-operative cognitive dysfunction in rats via activation of HTR2A/ERK/Nrf2 axis by targeting DNMT1.Cell death discovery · 2022Article
- Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report.Therapeutic advances in psychopharmacology · 2021Article
- Psychedelic-assisted therapy for functional neurological disorders: A theoretical framework and review of prior reports.Pharmacology research & perspectives · 2020Review
- Psychedelics as a Treatment for Alzheimer's Disease Dementia.Frontiers in synaptic neuroscience · 2020Review
- Psychedelic treatment of functional neurological disorder: a systematic review.Therapeutic advances in psychopharmacology · 2020Review
- Kinetic analysis of [BMC veterinary research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional neurological disorders are frequently encountered in clinical practice. They have a poor prognosis and treatment options are limited. Their etiology is unknown, but leading theories propose a disturbance of somatic self-representation: the mind perceives dysfunction of a body region despite intact motor and sensory pathways. Central to this model is the concept of an abnormal top-down cognitive influence upon sensorimotor function. There is growing interest in the use of 5-HT2A agonists in the management of neuropsychiatric conditions. Recent studies have shown that these agents induce changes in neural activity that disrupt hierarchical brain dynamics and modulate networks subserving self-related processing. Converging evidence suggests they may hold unique therapeutic potential in functional neurological disorders. This is of importance given the considerable personal and societal burden of this condition and we argue a clinical trial to test this hypothesis is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.